Spikevax market seen growing through 2030 as mRNA demand expands

The Business Research Company says the Spikevax vaccine market is set to keep growing through the forecast period, driven by COVID-19 infections, broader vaccination coverage and investment in healthcare systems. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Spikevax remains part of the global response to COVID-19, and the market’s direction reflects how governments, providers and public health systems continue to budget for vaccination. - Demand for booster doses, variant-tailored vaccines and broader immunization coverage could shape procurement and delivery decisions across regions.

What happened: - The Business Research Company published a market forecast for Spikevax through 2030. - The report says Spikevax market growth was driven historically by rapid global vaccine rollout, government immunization campaigns, mRNA advances, production gains and emergency regulatory approvals. - The report projects continued growth as attention shifts to next-generation mRNA vaccines, variant-specific immunizations, adult and pediatric vaccination coverage, and pandemic preparedness investments. - The report says North America held the largest share of the Spikevax market in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period.

The details: - Spikevax is formulated for people aged 6 months and older against COVID-19. - Spikevax’s active ingredient, elasomeran, is an mRNA molecule that directs cells to produce a spike protein matching the original SARS-CoV-2 strain. - The vaccine is designed to train the immune system to recognize and fight the virus and to reduce the severity of infection. - The report links market growth to rising COVID-19 infections worldwide. - The report points to new variants, waning immunity, relaxed public health restrictions, more indoor gatherings in colder seasons and uneven vaccine coverage as factors behind higher case numbers. - The report cites a March 2023 UK Office for National Statistics estimate that about 1.9 million people in the UK, or 2.9% of the population, reported long COVID symptoms. - The report says healthcare investment is also supporting market expansion through spending on treatments, hospitals, public health initiatives and vaccine access. - The report cites UK Office for National Statistics data showing total healthcare expenditure rose 5.6% nominally from 2022 to 2023, compared with 0.9% growth the prior year. - The report includes Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offers a free sample at the company’s sample request page. - The report also links to the full market report.

Between the lines: - The market thesis is less about a one-time pandemic surge and more about recurring demand tied to boosters, variant updates and preparedness spending. - The regional split suggests mature markets still drive revenue, while faster growth may come from expanding immunization infrastructure in Asia-Pacific. - The emphasis on logistics, digital tracking and booster strategies signals a market that depends on both product innovation and public-health execution.

What's next: - The report expects continued interest in mRNA platforms, variant-specific vaccines and delivery improvements such as better cold-chain logistics and digital tracking systems. - Ongoing healthcare spending and vaccination campaigns are likely to remain the main supports for market growth through the forecast period. - The company has positioned the report as part of its 2026 research updates, signaling more refined forecasting tools and market segmentation for buyers.